Immune-Related Fulminant Myocarditis in a Patient Receiving Ipilimumab Therapy for Relapsed Chronic Myelomonocytic Leukaemia
David D. Berg(Brigham and Women's Hospital), Anju Nohria(Brigham and Women's Hospital), Matthew Torre(Brigham and Women's Hospital), Robert F. Padera(Brigham and Women's Hospital), Muthiah Vaduganathan(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 46
Related Papers
The Global Health and Economic Burden of Hospitalizations for Heart Failure
|Journal of the American College of Cardiology|2014|2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k